1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

01 Mar 2024
Admin
News Article

LISCure Gets Clearance to Start Phase 2 Trial for LB-P8

LISCure Biosciences Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of LB-P8 for Primary Sclerosing Cholangitis (PSC)

Overview

Represents first ever live biotherapeutic product to receive IND clearance for PSC
Phase 2 clinical trial will evaluate the safety and efficacy, including clinical endpoints of LB-P8 LISCure Biosciences a leading clinical-stage biopharmaceutical company focused on discovering and developing innovative microbiome-based therapies, announces the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for LB-P8, a live biotherapeutic product (LBP) intended to treat primary sclerosing cholangitis (PSC). LISCure anticipates treating the first patient in the upcoming months and expects topline results for Part 1 in the first half of 2025.

About PSC

PSC is a rare, chronic, cholestatic liver disease with very high unmet medical needs where there are no approved drugs.
PSC can benefit from microbiome drugs because PSC is linked to the ""gut-liver"" axis and is strongly associated with total gastrointestinal risk and inflammatory bowel disease (IBD).
LB-P8, designed to treat inflammation and fibrosis and to modulate bile acids, is expected to perform significantly well in clinical trials and hold a high position of success rate in drug development.

Safety Confirmation

LISCure confirmed the safety, tolerability, and key biomarkers of LB-P8 in a Phase 1 study and received Orphan Drug Designation (ODD) for the treatment of PSC from the U.S. FDA. LB-P8 was presented in oral presentations at the American Association for the Study of Liver Diseases (AASLD) every year for the past two years.

Words from LISCure

"We are thrilled to obtain IND clearance to investigate LB-P8 for patients with PSC and are excited about the prospects of what this new class of medicines may mean for patients in need,"" said Hwasup Chin, Chief Executive Officer of LISCure Biosciences. ""LB-P8 is receiving considerable attention from patient advocacy, physicians, companies, and other stakeholders. To meet their expectations, we will expedite development and offer new treatment opportunities to patients expeditiously."

About LISCure Biosciences

LISCure Biosciences Inc. is a clinical-stage company developing microbe-oriented new drugs based on innovative modalities for the areas of high unmet medical needs such as oncology, metabolic diseases, neurosciences, and immunology.
LISCure uses a single strain, microbial-derived metabolites, and extracellular vesicles (EVs) to create ""Next Generation Microbial Therapeutics"" with precision targets.
LISCure has its own screening platform technology based on a proprietary in-house microorganism bank and is dedicated to developing first-in-class new drugs against diseases for which existing microbiome treatments have been rarely attempted.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!